The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults
The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults
复制标题
DOI：
10.1159/000338998
复制
发表时间：
2013-01-01
影响因子：
2.8
通讯作者：
de Marco, Roberto
中科院分区：
文献类型：
--
作者：
Accordini, Simone;Corsico, Angelo G.;de Marco, Roberto
背景资料：本研究旨在根据疾病控制程度[如2006年全球哮喘倡议（GINA）指南所定义]，对欧洲成人持续性哮喘的经济成本进行真实评估。研究方法：对462例年龄在30-54岁的持续性哮喘患者（根据2002年GINA定义）进行了一项基于患病率的疾病成本研究，这些患者是在11个欧洲国家的一般人群样本中确定的，并在1999年至2002年期间的欧洲共同体呼吸健康调查II中进行了临床检查。费用估计数是根据2004年的费率、工资和价格（在国家一级从官方来源获得），从社会角度采用自下而上的方法计算的，然后转换为2010年的数值。结果如下：每例患者的平均总成本为1，583欧元，主要由间接成本（即损失的工作日和有限的非工作相关活动日62.5%）驱动。11个欧洲国家30-54岁人口的预期总成本为43亿欧元（扩展到整个欧洲15 - 64岁人口时为193亿欧元）。每例患者的平均总费用范围为509欧元（哮喘控制）至2，281欧元（疾病未控制）。慢性咳嗽或痰和高BMI显著增加了个人总成本。结论：在欧洲成年人中，持续性哮喘的费用随着疾病控制的减少而急剧增加。因此，通过对欧洲成年患者的适当管理，可以节省大量费用。版权所有（c）2012 S. Karger AG，巴塞尔
Background: This study is aimed at providing a real-world evaluation of the economic cost of persistent asthma among European adults according to the degree of disease control [as defined by the 2006 Global Initiative for Asthma (GINA) guidelines]. Methods: A prevalence-based cost-of-illness study was carried out on 462 patients aged 30-54 years with persistent asthma (according to the 2002 GINA definition), who were identified in general population samples from 11 European countries and examined in clinical settings in the European Community Respiratory Health Survey II between 1999 and 2002. The cost estimates were computed from the societal perspective following the bottom-up approach on the basis of rates, wages and prices in 2004 (obtained at the national level from official sources), and were then converted to the 2010 values. Results: The mean total cost per patient was EUR 1,583 and was largely driven by indirect costs (i.e. lost working days and days with limited, not work-related activities 62.5%). The expected total cost in the population aged 30-54 years of the 11 European countries was EUR 4.3 billion (EUR 19.3 billion when extended to the whole European population aged from 15 to 64 years). The mean total cost per patient ranged from EUR 509 (controlled asthma) to EUR 2,281 (uncontrolled disease). Chronic cough or phlegm and having a high BMI significantly increased the individual total cost. Conclusions: Among European adults, the cost of persistent asthma drastically increases as disease control decreases. Therefore, substantial cost savings could be obtained through the proper management of adult patients in Europe. Copyright (c) 2012 S. Karger AG, Basel